Isolation of nanobodies with potential to reduce patients´ IgE binding to Bet v 1 (68/100 characters).

We identified high-affinity Bet v 1-specific nanobodies that recognize an important IgE-epitope and reduce allergen-induced basophil activation revealing the first proof that allergen-specific nanobodies are useful tools for future treatment of pollen allergy.